The blog is a place to post your thoughts and ideas.

We tend to think of antibiotic resistance somewhat parochially as the problem that exists in the United States, and possibly in other high-income countries. The national solutions have to do with infection control in hospitals, physician prescribing, etc.—all linked to a formal medical care system that works more or less as we expect. But the larger world is quite different and we have to start looking at antibiotics as shared global resources. In most developing countries, antibiotics are treated more like aspirin—available to anyone with the money to pay for them (even if a prescription is technically required) and in quantities at the discretion of the buyer. One or two tablets may be enough to make a child feel better, which is what a parent cares about. For many people, sheer lack of money has limited access to antibiotics. But a growing middle class even in low-income countries, such as India, China, and Brazil means that US consumption will be dwarfed. And health care system controls are developing much more slowly in these countries than is purchasing power. After several years of studying antibiotic resistance in the US and identifying policy and economic strategies through Extending the Cure, Resources for the Future (RFF) is now to expand to the developing world. The “Global Antibiotic Resistance Partnership”—GARP for short—is a new project that will begin in November 2009 with funding from the Bill & Melinda Gates Foundation. Local groups in India, China, Vietnam, Kenya and South Africa will be organized and assisted by RFF and other partners to study the situation in each country and then move on to develop a strategy through policy and economic incentives to rationalize antibiotic use. Watch this space for GARP news as we begin this exciting project.